Pfizer (PFE), BioNTech (BNTX) Start Rolling Submission to FDA for Booster - Bloomberg
Tweet
Share
E-mail
Get Alerts PFE Hot Sheet
Price: $28.45 -1.25%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 6.9%
EPS Growth %: -12.6%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 6.9%
EPS Growth %: -12.6%
Join SI Premium – FREE
(Updated - August 25, 2021 12:04 PM EDT)
Pfizer (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) started their rolling submission to the FDA for booster vaccines, Bloomberg reported. The companies intend to finish the sBLA submissions by week-end.
The companies will submit data to the EMA and other regulators in weeks.
Data showed robust neutralizing antibodies.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA grants accelerated approval to AstraZeneca's camizestrant combo
- Pulmovant to present Phase 2 mosliciguat results at ERS Congress
- Agilent launches FDA-cleared S540MD slide scanner in the U.S.
Create E-mail Alert Related Categories
Corporate News, FDA, Hot FDA NewsRelated Entities
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
